医学
优势比
内科学
全基因组关联研究
剩余风险
他汀类
心肌梗塞
置信区间
单核苷酸多态性
次等位基因频率
急性冠脉综合征
生物信息学
肿瘤科
心脏病学
遗传学
基因型
生物
基因
作者
Wei‐Qi Wei,Xiaohui Li,QiPing Feng,Michiaki Kubo,Iftikhar J. Kullo,Peggy L. Peissig,Elizabeth W. Karlson,Gail Pairitz Jarvik,Ming Ta Michael Lee,Ning Shang,Eric A. Larson,Todd L. Edwards,Christian M. Shaffer,Jonathan D. Mosley,Shiro Maeda,Momoko Horikoshi,Marylyn DeRiggi Ritchie,Marc S. Williams,Eric Berg Larson,David R. Crosslin
出处
期刊:Circulation
[Lippincott Williams & Wilkins]
日期:2018-04-27
卷期号:138 (17): 1839-1849
被引量:93
标识
DOI:10.1161/circulationaha.117.031356
摘要
BACKGROUND: Coronary heart disease (CHD) is a leading cause of death globally. Although therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and the incidence of CHD, additional events occur despite statin therapy in some individuals. The genetic determinants of this residual cardiovascular risk remain unknown. METHODS: We performed a 2-stage genome-wide association study of CHD events during statin therapy. We first identified 3099 cases who experienced CHD events (defined as acute myocardial infarction or the need for coronary revascularization) during statin therapy and 7681 controls without CHD events during comparable intensity and duration of statin therapy from 4 sites in the Electronic Medical Records and Genomics Network. We then sought replication of candidate variants in another 160 cases and 1112 controls from a fifth Electronic Medical Records and Genomics site, which joined the network after the initial genome-wide association study. Finally, we performed a phenome-wide association study for other traits linked to the most significant locus. RESULTS: ). In the replication cohort, rs10455872 was also associated with CHD events (odds ratio, 1.71; 95% confidence interval, 1.14-2.57; P=0.009). The association of this single nucleotide polymorphism with CHD events was independent of statin-induced change in low-density lipoprotein cholesterol (odds ratio, 1.62; 95% confidence interval, 1.17-2.24; P=0.004) and persisted in individuals with low-density lipoprotein cholesterol ≤70 mg/dL (odds ratio, 2.43; 95% confidence interval, 1.18-4.75; P=0.015). A phenome-wide association study supported the effect of this region on coronary heart disease and did not identify noncardiovascular phenotypes. CONCLUSIONS: Genetic variations at the LPA locus are associated with CHD events during statin therapy independently of the extent of low-density lipoprotein cholesterol lowering. This finding provides support for exploring strategies targeting circulating concentrations of lipoprotein(a) to reduce CHD events in patients receiving statins.
科研通智能强力驱动
Strongly Powered by AbleSci AI